Literature DB >> 9681832

Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA.

S Kondo1, Y Kondo, G Li, R H Silverman, J K Cowell.   

Abstract

Telomerase is the RNA-protein complex which elongates telomeric DNA (TTAGGG)n and appears to play an important role in cellular immortalization. The almost exclusive expression of telomerase in tumor cells, and not in most normal cells, offers an exciting opportunity for therapy by inhibiting its function. Here, we have investigated the effect of inhibition of telomerase on the growth and survival of human malignant glioma cells in vitro and in vivo by using a 19-mer antisense oligonucleotide against human telomerase RNA linked to a 2',5'-oligoadenylate (2-5A). 2-5A antisense functions by activating the endoribonuclease, RNase L, resulting in the degradation of single stranded, targeted RNA. We have shown that the 2-5A antisense treatment effectively suppressed tumor cell growth and survival in vitro. Furthermore, treatment of tumors grown in nude mice with the antisense oligonucleotide inhibited survival of the tumor cells. TUNEL assays suggest that this effect is mediated through the induction of apoptosis. Targeting telomerase RNA with 2-5A antisense, therefore, may represent an effective and novel approach for treatment of a broad range of cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681832     DOI: 10.1038/sj.onc.1201885

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

Review 1.  Antisense cancer therapy: the state of the science.

Authors:  D M Kushner; R H Silverman
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Antisense telomerase RNA induced human gastric cancer cell apoptosis.

Authors:  Fang-Xin Zhang; Xue-Yong Zhang; Dai-Ming Fan; Zi-Yun Deng; Yan Yan; Han-Ping Wu; Jun-Jie Fan
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

3.  Molecular targeting of cancer: telomeres as targets.

Authors:  R Hodes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 4.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

Review 5.  Tiptoeing to chromosome tips: facts, promises and perils of today's human telomere biology.

Authors:  J Fajkus; M Simícková; J Maláska
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

6.  Effective inhibition of cancer cell growth by a novel tripartite transfection complex containing ribbon antisense molecules to hTR.

Authors:  Jong-Gu Park
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

7.  A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation.

Authors:  M M Kim; M A Rivera; I L Botchkina; R Shalaby; A D Thor; E H Blackburn
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

8.  Targeting human telomerase for cancer therapeutics.

Authors:  Lionel Guittat; Patrizia Alberti; Dennis Gomez; Anne De Cian; Gaëlle Pennarun; Thibault Lemarteleur; Chafke Belmokhtar; Rajaa Paterski; Hamid Morjani; Chantal Trentesaux; Eliane Mandine; François Boussin; Patrick Mailliet; Laurent Lacroix; Jean-François Riou; Jean-Louis Mergny
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

9.  Telomerase activity and cell apoptosis in colon cancer cell by human telomerase reverse transcriptase gene antisense oligodeoxynucleotide.

Authors:  Ying-An Jiang; He-Sheng Luo; You-Yuan Zhang; Li-Fang Fan; Chong-Qing Jiang; Wei-Jin Chen
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 10.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.